Axitinib for treating advanced renal cell carcinoma after failure of prior systemic treatment

  • Technology appraisal guidance
  • TA333
  • Published: 
Download (PDF)

Why has NICE said this?

Axitinib was recommended because the benefits to patients justify its cost.

NICE looks at how well treatments work in relation to how much they cost compared with other treatments available on the NHS.

  • Information Standard